ABSTRACT
Abstract Stanozolol (ST) is a synthetic androgen with high anabolic potential. Although it is known that androgens play a positive role in bone metabolism, ST action on bone cells has not been sufficiently tested to support its clinical use for bone augmentation procedures. Objective: This study aimed to assess the effects of ST on osteogenic activity and gene expression in SaOS-2 cells. Material and Methods: SaOS-2 deposition of mineralizing matrix in response to increasing doses of ST (0-1000 nM) was evaluated through Alizarin Red S and Calcein Green staining techniques at 6, 12 and 24 days. Gene expression of runt-related transcription factor 2 (RUNX2), vitamin D receptor (VDR), osteopontin (SPP1) and osteonectin (ON) was analyzed by RT-PCR. Results: ST significantly influenced SaOS-2 osteogenic activity: stainings showed the presence of rounded calcified nodules, which increased both in number and in size over time and depending on ST dose. RT-PCR highlighted ST modulation of genes related to osteogenic differentiation. Conclusions: This study provided encouraging results, showing ST promoted the osteogenic commitment of SaOS-2 cells. Further studies are required to validate these data in primary osteoblasts and to investigate ST molecular pathway of action.
Subject(s)
Humans , Osteogenesis/drug effects , Stanozolol/pharmacology , Gene Expression/drug effects , Anabolic Agents/pharmacology , Osteoblasts/drug effects , Time Factors , Calcification, Physiologic/drug effects , Linear Models , Osteonectin/analysis , Osteonectin/drug effects , Reproducibility of Results , Analysis of Variance , Receptors, Calcitriol/analysis , Receptors, Calcitriol/drug effects , Cell Line, Tumor/drug effects , Core Binding Factor Alpha 1 Subunit/analysis , Core Binding Factor Alpha 1 Subunit/drug effects , Osteopontin/analysis , Osteopontin/drug effects , Real-Time Polymerase Chain ReactionABSTRACT
A close correlation between vitamin D receptor (VDR) abundance and cell proliferation rate has been shown in NIH-3T3 fibroblasts, MCF-7 breast cancer and in HL-60 myeloblastic cells. We have now determined if this association occurs in other leukemic cell lines, U937 and K562, and if VDR content is related to c-myc expression, which is also linked to cell growth state. Upon phorbol myristate acetate (PMA) treatment, cells from the three lineages (HL-60, U937 and K562) differentiated and expressed specific surface antigens. All cell lines analyzed were growth inhibited by PMA and the doubling time was increased, mainly due to an increased fraction of cells in the G0/G1 phase, as determined by flow cytometry measurements of incorporated bromodeoxyuridine and cell DNA content. C-myc mRNA expression was down-regulated and closely correlated to cell growth arrest. However, VDR expression in leukemic cell lines, as determined by immunofluorescence and Northern blot assays, was not consistently changed upon inhibition of cell proliferation since VDR levels were down-regulated only in HL-60 cells. Our data suggest that VDR expression cannot be explained simply as a reflection of the leukemic cell growth state.
Subject(s)
Humans , Carcinogens/pharmacology , Cell Differentiation/physiology , Gene Expression Regulation, Neoplastic/physiology , Leukemia/genetics , Receptors, Calcitriol/genetics , Tetradecanoylphorbol Acetate/pharmacology , Antibodies, Monoclonal , Cells, Cultured , Down-Regulation , Fluorescent Antibody Technique , Gene Expression Regulation, Neoplastic/drug effects , Growth Inhibitors , HL-60 Cells , K562 Cells , Phenotype , Receptors, Calcitriol/drug effects , RNA/isolation & purification , U937 CellsABSTRACT
Estrogen is essential for growth and development of 30 per cent of malignant breast tumors and concentration of estrogen receptor (ER) is an indicator of hormone dependence. The effects of estradiol-l7beta (E2) on growth promotion and vitamin D (VDR) and progesterone (PR) receptor modulation were evaluated in hormone-dependent (MCF-7, T47D) and -independent (MDA-MB-231) breast carcinoma cells lines. 10(-7)M E2 stimulated the proliferation of MCF-7 and T47D cells the extent of which was correlated to ER content, being sensitive to growth inhibition of 10(-6) M tamoxifen. No effect on growth and PR levels was observed in E2 treated MDA-MB-231 cells. A statistically significant 10(-7)M E(2-)mediated induction of VDR was verified in T47D cells which was abolished by 10(-6)M tamoxifen, revealing an ER-mediated mechanism. 10(-6)M tamoxifen treatment alone upregulated VDR levels in T47D cells, suggesting that this drug may utilize a distinct pathway (ER-independent) for stimulation of VDR content, by a mechanism, now in progress, to be elucidated. These results, taken together, suggest the importance of VDR level assessment as new a prognostic indicator in breast carcinoma.